Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04866108
Other study ID # HMPL-013-FLAG-C104
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 8, 2021
Est. completion date June 2024

Study information

Verified date August 2022
Source Beijing Friendship Hospital
Contact Zhigang Bai
Phone +86-010-63138712
Email baizhigang@ccmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.


Description:

Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, this phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable for intravenous chemotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 49
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years old at the time of signing the informed consent; 2. Histologically or cytologically confirmed unresectable metastatic colorectal cancer; 3. Haven't received systematic therapy after diagnosis of metastatic colorectal cancer; 4. Intolerable to standard treatment of oxaliplatin- or irinotecan-based intravenous combination therapy; 5. At least one measurable lesion(s); 6. ECOG PS 0-2; 7. Life expectancy=3 months; 8. Adequate organ and bone marrow functions; 9. Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration; 10. Willingness and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure. Exclusion Criteria: 1. Previous treatment with VEGFR inhibition; 2. Participating in other drug clinical trials within 4 weeks before recruited; 3. Have received other systemic anti-tumor therapies within 4 weeks before recruited; 4. Non-controlled hypertension after monotherapy, that is, systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg; 5. Proteinuria = 2+ (1.0g/24hr); 6. Clinically significant electrolyte abnormality; 7. Clinically significant cardiovascular diseases; 8. Thromboembolism or arteriovenous events occurred 6 months before recruited; 9. =grade 3 bleeding events 4 weeks before recruited; 10. Evidence of CNS metastasis; 11. Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI; 12. Active, symptomatic interstitial lung disease causing dyspnea (= grade 2 dyspnea), pleural effusion or ascites; 13. History of organ transplantation; 14. APTT >1.5×ULN or INR>1.5; 15. History of HIV infection or active hepatitis B / C; 16. Allergic to fruquintinib and / or capecitabine; 17. Pregnant or lactating women; 18. Clinically detectable secondary primary malignancies at the time of enrollment (excluding fully treated basal cell carcinoma of the skin or carcinoma in situ of the cervix); 19. Patients who are not suitable for the study judged by the researchers.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
fruquintinib plus capecitabine
oral fruquintinib plus capecitabine

Locations

Country Name City State
China Beijing Friendship Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) version. 1.1 From Baseline to primary completion date, about 3 years
Secondary Overall Survival (OS) OS is determined from the date of treatment to death from any cause or the last follow-up date From Baseline to primary completion date, about 3 years
Secondary Progression Free Survival (PFS) PFS is determined from the date of treatment to PD or death from any cause From Baseline to primary completion date, about 3 years
Secondary Disease Control Rate (DCR) DCR according to Response Evaluation Criteria in Solid Tumors (RECIST) version. 1.1 From Baseline to primary completion date, about 3 years
Secondary Adverse Events and Serious Adverse Events Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0. From Baseline to primary completion date, about 3 years
Secondary Quality of Life (QoL) Quality of life is assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30. It will be evaluated at Screening, Tumor Assessment Visit and End of Treatment visit. From Baseline to primary completion date, about 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05068206 - A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx Phase 2
Not yet recruiting NCT04131803 - Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer N/A
Recruiting NCT03692429 - alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells Phase 1
Recruiting NCT04991948 - Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer Phase 1
Recruiting NCT06107413 - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab Phase 2
Completed NCT01802684 - OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer Phase 2
Recruiting NCT04160416 - mXELOXIRI Combined With Molecular Targeted Drug in mCRC Phase 2